State Street Corp Protagonist Therapeutics, Inc Transaction History
State Street Corp
- $2.41 Trillion
- Q3 2024
A detailed history of State Street Corp transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, State Street Corp holds 3,183,542 shares of PTGX stock, worth $133 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,183,542
Previous 2,082,324
52.88%
Holding current value
$133 Million
Previous $72.2 Million
98.29%
% of portfolio
0.01%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$244 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$240 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$226 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$176 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ2.45MShares$102 Million35.09% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.04B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...